(PharmaNewsWire.Com, May 21, 2019 ) This report analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
On basis of technology, the HLA typing for transplant market is categorized into molecular assay technology [including PCR-based (Sequence-specific oligonucleotide and sequence-specific primer-PCR) and sequencing-based (next-generation sequencing and Sanger sequencing)] and non-molecular assay technology (includes serological and mixed lymphocyte culture assays). The molecular assay segment is expected to account for the larger share of the global HLA typing for transplant market in 2016. The sequencing-based molecular assay segment is projected to grow faster than the PCR-based molecular assay segment, growing at a double-digit CAGR during 2016–2021.
Growth in the sequencing-based molecular assay segment is mainly driven by the growing market demand for high-throughput DNA sequencers in HLA typing, rising end-user preference for low-cost and efficient DNA sequencing technologies, expansion in application horizons of NGS in tissue typing, and increasing usage of NGS systems among researchers and diagnostic laboratories. The PCR-based molecular assay segment is expected to hold a larger share of the global HLA typing for transplant market for molecular assay technology in 2016.
Factors such as growing number of solid organ, soft tissue, and stem cell transplantations; technological advancements; and increased funding, research grants, and public-private investments are the key market drivers for the HLA-based transplant diagnostics industry. However, high device costs associated with NGS and PCR-based devices and limited medical reimbursements for organ donation and transplantation procedure restrain the growth of the market to a certain extent. Furthermore, the technological shift from serological assays to gene-based HLA profiling and improving healthcare infrastructure across developing countries provide opportunities for players in the HLA typing for transplant market. The significant gap between the number of organs donated and the number of organs required annually is a major challenge limiting the growth of the global HLA typing for transplant market.
In 2016, North America and Europe are expected to be the mature markets for HLA typing products for transplant. However, emerging regions such as Asia-Pacific (including Japan, China, and India) are expected to become the new revenue-generating pockets in the HLA typing for transplant market in the next five years. The North America is expected to hold the largest share of the global HLA typing for transplant market in 2016; it is projected to grow at the highest CAGR during the forecast period owing to easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, increasing prevalence of target diseases (such as cancer, heart failure, and renal diseases) in the U.S. and Canada, and continuous technological advancements in the field of HLA-based transplant diagnostics.
As of 2015, the key players in the HLA typing for transplant market included Thermo Fischer Scientific, Inc. (U.S.), Immucor, Inc. (U.S), Olerup SSp AB (Sweden), QIAGEN, Inc. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Affymetrix, Inc. (U.S.), Illumina Inc. (U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc. (U.S.), among others.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
